These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20379837)

  • 1. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma.
    Shimada M; Sugimoto K; Iwahashi S; Utsunomiya T; Morine Y; Imura S; Ikemoto T
    J Gastroenterol; 2010 Aug; 45(8):896-902. PubMed ID: 20379837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis.
    Thanan R; Pairojkul C; Pinlaor S; Khuntikeo N; Wongkham C; Sripa B; Ma N; Vaeteewoottacharn K; Furukawa A; Kobayashi H; Hiraku Y; Oikawa S; Kawanishi S; Yongvanit P; Murata M
    Free Radic Biol Med; 2013 Dec; 65():1464-1472. PubMed ID: 23917144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma.
    Fan L; He F; Liu H; Zhu J; Liu Y; Yin Z; Wang L; Guo Y; Wang Z; Yan Q; Huang G
    BMC Cancer; 2011 Jul; 11():320. PubMed ID: 21798073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of CD133+ parenchymal cells in the liver: histology and culture.
    Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y
    World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1α for Intrahepatic Cholangiocarcinoma.
    Ohta S; Morine Y; Imura S; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Wada Y; Yamashita S; Bando Y; Shimada M
    Anticancer Res; 2019 Nov; 39(11):6025-6033. PubMed ID: 31704828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma.
    Morine Y; Shimada M; Utsunomiya T; Imura S; Ikemoto T; Mori H; Hanaoka J; Kanamoto M; Iwahashi S; Miyake H
    Hepatogastroenterology; 2011; 58(110-111):1439-44. PubMed ID: 21940327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
    Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
    Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.
    Morine Y; Shimada M; Iwahashi S; Utsunomiya T; Imura S; Ikemoto T; Mori H; Hanaoka J; Miyake H
    Surgery; 2012 Mar; 151(3):412-9. PubMed ID: 21982637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong expression of CD133 is associated with increased cholangiocarcinoma progression.
    Leelawat K; Thongtawee T; Narong S; Subwongcharoen S; Treepongkaruna SA
    World J Gastroenterol; 2011 Mar; 17(9):1192-8. PubMed ID: 21448425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Central Hypo-enhancement in the Hepatic Arterial Phase of Dynamic Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma.
    Teraoku H; Morine Y; Uyama N; Ikemoto T; Iwahashi S; Saito Y; Takasu C; Imura S; Harada M; Shimada M
    World J Surg; 2020 Jul; 44(7):2350-2358. PubMed ID: 32152739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of long non‑coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma.
    Bai JG; Tang RF; Shang JF; Qi S; Yu GD; Sun C
    Mol Med Rep; 2018 Apr; 17(4):5328-5335. PubMed ID: 29393466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma.
    Tokuda K; Morine Y; Saito Y; Yamada S; Miyazaki K; Yamashita S; Okikawa S; Ikemoto T; Imura S; Shimada M
    Int J Clin Oncol; 2020 Dec; 25(12):2083-2089. PubMed ID: 32869120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
    Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
    World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of microvessel density in intrahepatic cholangiocarcinoma.
    Bunsiripaiboon P; Sornmayura P; Wilasrusmee C; Lertsithichai P
    J Med Assoc Thai; 2010 Jan; 93(1):66-72. PubMed ID: 20196413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection.
    Morine Y; Imura S; Ikemoto T; Iwahashi S; Saito YU; Shimada M
    Anticancer Res; 2017 Oct; 37(10):5701-5705. PubMed ID: 28982889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.
    Morine Y; Shimada M; Utsunomiya T; Imura S; Ikemoto T; Hanaka J; Kanamoto M; Kurita N; Miyake H
    Surg Today; 2012 Jan; 42(2):135-40. PubMed ID: 22143355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma.
    Guo S; Liu HD; Liu YF; Liu L; Sun Q; Cui XJ
    Tumour Biol; 2015 Jan; 36(1):353-64. PubMed ID: 25262276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
    Yang SZ; Wang AQ; Du J; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
    World J Gastroenterol; 2016 Jul; 22(25):5814-21. PubMed ID: 27433094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma.
    Hirashita T; Iwashita Y; Ohta M; Komori Y; Eguchi H; Yada K; Kitano S
    J Gastrointest Surg; 2012 Apr; 16(4):842-8. PubMed ID: 22246855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.
    Ikeda H; Harada K; Sato Y; Sasaki M; Yoneda N; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Am J Clin Pathol; 2013 Sep; 140(3):329-40. PubMed ID: 23955451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.